Cariprazine (Vraylar) and Ketamine Therapy | Tovani Health
Vraylar (Cariprazine) — Atypical antipsychotic (D3-preferring partial agonist)
Verdict at Tovani Health
Compatible; partial-agonist profile makes antidepressant attenuation less pronounced than full antagonists.
Cariprazine and ketamine are compatible. As a D2/D3 partial agonist (similar mechanistic family to aripiprazole and brexpiprazole), it has a lighter side-effect footprint than olanzapine or risperidone. The theoretical antidepressant-attenuation concern for ketamine is smaller for partial agonists than for full antagonists.
If you take Vraylar regularly and are considering at-home ketamine therapy, the combination is safe with monitoring or dose adjustment. This page covers the brief pharmacologic context and what we do at intake.
How Vraylar interacts with ketamine
Cariprazine is a partial agonist at D2 and D3 receptors with D3-preference. Also has 5-HT1A partial agonism and 5-HT2A antagonism. Long half-life (1-3 weeks for active metabolites) means steady-state effect.
What we do at intake
Disclose dose and indication. The long half-life means timing changes don't help much; we plan around the steady-state effect.
Bottom line
Cariprazine and ketamine are compatible. As a D2/D3 partial agonist (similar mechanistic family to aripiprazole and brexpiprazole), it has a lighter side-effect footprint than olanzapine or risperidone. The theoretical antidepressant-attenuation concern for ketamine is smaller for partial agonists than for full antagonists.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Vraylar (Cariprazine) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression. Veraart JKE, Smith-Apeldoorn SY, et al.. International Journal of Neuropsychopharmacology. 2021. PMID: 34170315
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 16, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.